STOCK TITAN

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) CEO Richard Pops to provide corporate update at 42nd Annual J.P. Morgan Healthcare Conference
Positive
  • None.
Negative
  • None.

DUBLIN, Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-42nd-annual-jp-morgan-healthcare-conference-302025512.html

SOURCE Alkermes plc

The presentation will take place on Wednesday, Jan. 10, 2024 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT)

The live webcast may be accessed under the Investors tab on www.alkermes.com

The webcast will be archived for 14 days
Alkermes plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.